These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29733899)

  • 1. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
    Rice ML; Wong B; Horn PS; Yang MB
    J AAPOS; 2018 Jun; 22(3):192-196. PubMed ID: 29733899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
    Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
    J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
    Dooley JM; Bobbitt SA; Cummings EA
    Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
    Biggar WD; Harris VA; Eliasoph L; Alman B
    Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
    Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
    J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
    McAdam LC; Mayo AL; Alman BA; Biggar WD
    Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deflazacort treatment of Duchenne muscular dystrophy.
    Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
    J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
    Wong BL; Cook T; Miller H
    J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
    Biggar WD; Skalsky A; McDonald CM
    J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
    Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
    J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
    [No Abstract]   [Full Text] [Related]  

  • 17. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
    Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
    J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
    [No Abstract]   [Full Text] [Related]  

  • 19. Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.
    Abutaleb ARA; McNally EM; Khan SS; Anderson AS; Carr JC; Wilcox JE
    JAMA Cardiol; 2018 Oct; 3(10):1006-1010. PubMed ID: 30167630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
    Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
    Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.